Absci to Participate in the 22nd Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, has announced its participation in the 22^nd Annual Needham Virtual Healthcare Conference. The management presentation is scheduled for Thursday, April 20^th, at 1:30 p.m. ET (10:30 a.m. PT). Interested parties can access the live and archived webcast through the company's investor relations website.

Absci specializes in combining AI with scalable wet lab technologies to enhance drug development, aiming to accelerate time to clinic and improve success rates. Its Integrated Drug Creation™ platform allows rapid screening and validation of drug candidates. The company is headquartered in Vancouver, WA, with additional facilities in New York and Zug, Switzerland.

VANCOUVER, Wash. and NEW YORK, April 06, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming 22^nd Annual Needham Virtual Healthcare Conference.

Absci management is scheduled to present on Thursday, April 20^th at 1:30 p.m. Eastern Time (10:30 a.m. Pacific Time). Interested parties may access a live and archived webcast on the company’s investor relations website at: investors.absci.com.

About Absci

Absci is a generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Our vision is to deliver breakthrough therapeutics at the click of a button, for everyone. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn (@absci), Twitter (@Abscibio), and YouTube.

Availability of Other Information about Absci

Investors and others should note that we routinely communicate with investors and the public using our website (www.absci.com) and our investor relations website (investors.absci.com), including without limitation, through the posting of investor presentations, SEC filings, press releases, public conference calls and webcasts on these websites, as well as on Twitter, LinkedIn and YouTube. The information that we post on these websites and social media outlets could be deemed to be material information. As a result, investors, the media, and others interested in Absci are encouraged to review this information on a regular basis. The contents of our website and social media postings, or any other website that may be accessed from our website or social media postings, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Investor Contact
investors@absci.com

Media Contact
press@absci.com

 

FAQ

When will Absci present at the 22nd Annual Needham Virtual Healthcare Conference?

Absci will present on April 20th, 2023, at 1:30 p.m. ET.

How can I access the Absci presentation webcast?

The webcast can be accessed live and archived on Absci's investor relations website.

What is the focus of Absci's drug creation technology?

Absci focuses on using generative AI and wet lab technologies to create biologics more efficiently.

What is Absci's Integrated Drug Creation™ platform?

It is a platform that accelerates drug development by optimizing various drug characteristics simultaneously.

Where is Absci headquartered?

Absci is headquartered in Vancouver, WA, with additional locations in New York and Zug, Switzerland.